SYSTEMIC LUPUS ERYTHEMATOSUS

This study tests whether the shingles vaccine is safe and works well for people with lupus, a condition that weakens the immune system. About 224 adults with lupus will receive either the vaccine or a placebo to see if it causes lupus flare-ups. The goal is to confirm the vaccine…

This study tests whether the drug anifrolumab can improve blood vessel health and reduce inflammation in people with lupus, who face higher risks of heart attacks and strokes. About 45 adults with lupus will receive either anifrolumab or a placebo through IV infusions over 8 mont…

This study compares a newer drug, telitacicept, to the standard treatment cyclophosphamide for lung scarring (interstitial lung disease) caused by lupus. About 100 adults with mild-to-moderate lung involvement will receive one of the two drugs for a year. The goal is to see which…

This study is testing a drug called belimumab in 350 adults who have had lupus for less than 2 years and still have active symptoms despite standard treatment. The goal is to see if belimumab can help control the disease and reduce flares over 3 years. Participants will receive w…

This early-stage study tests an experimental drug called GSK5926371 in people with lupus and similar autoimmune diseases. The drug is designed to target and calm specific immune cells that mistakenly attack the body. The main goal is to check if the drug is safe and how the body …

This early-stage study tests the safety of a new drug called AZD5492 in 72 adults with lupus, myositis, or rheumatoid arthritis. Participants receive either one or two doses of the drug and are monitored for side effects over about 6 months. The goal is to find a safe dose and un…

This study tests two drugs, inebilizumab and blinatumomab, in 220 adults with hard-to-treat lupus or rheumatoid arthritis. The goal is to see if they are safe and can help control disease symptoms. Participants will receive the drugs and be monitored for side effects and improvem…

This study tests a new treatment called anti-CD19/BCMA universal CAR-T cells for people with severe autoimmune diseases like rheumatoid arthritis, lupus, and scleroderma. The therapy uses specially engineered immune cells to target and reduce harmful B cells that drive the diseas…

This study looks at the long-term safety of a drug called ianalumab for people with systemic lupus erythematosus (SLE), a chronic autoimmune disease. About 550 adults who already completed a previous ianalumab study will receive either the drug or a placebo. The main goal is to t…

This study tests a new treatment for people with autoimmune disorders like systemic sclerosis, lupus, and lupus nephritis. It combines a special immune cell therapy (AD-PluReceptor-NK cells) with a drug called tafasitamab and chemotherapy. The goal is to find a safe dose and see …

This study tests a new treatment for people with lupus, scleroderma, dermatomyositis, or polymyositis. It uses the patient's own immune cells, which are modified in a lab to find and attack faulty B cells that drive the disease. The goal is to safely control the autoimmune attack…

This early-phase study tests a new, fast-made CAR-T cell therapy for people with severe lupus that hasn't improved with standard treatments. About 18 adults will receive their own modified immune cells to see if it safely reduces disease activity. The goal is to control lupus sym…

This early-stage study tests a new drug called A-319 in 25 adults with active or treatment-resistant systemic lupus erythematosus (SLE). The drug is designed to target and help control overactive immune cells. The main goal is to see if it is safe and tolerable, while also checki…

This study is for people who have both an autoimmune disease (like rheumatoid arthritis, lupus, or multiple sclerosis) and advanced cancer that has spread or cannot be removed. It tests a drug called nivolumab, which helps the immune system fight cancer, given alone or with other…

This study tests an experimental drug called VENT-03 in 24 adults with active lupus skin disease (cutaneous lupus), with or without systemic lupus. For the first 4 weeks, some get the drug and some get a placebo; then everyone gets VENT-03 for 8 more weeks. The goal is to see if …

This study tests a new medicine called E6742 for people with systemic lupus erythematosus (SLE), a chronic autoimmune disease. About 256 adults with active lupus will receive either E6742 or a placebo to see if the drug reduces disease activity better than placebo. The main goal …

This early-stage study tests an experimental drug (GSK4527363) in healthy volunteers and people with active lupus or lung scarring linked to connective tissue disease. The main goal is to check safety and how the drug moves through the body. About 142 participants will take part …

This early-phase study tests a new treatment called HN2301 in 30 adults with lupus, scleroderma, or rheumatoid arthritis. The goal is to see if it is safe and can reduce disease activity by reprogramming the body's immune cells. Participants will receive a single dose and be moni…

This early-stage study tests a new drug, UB-VV410, in 21 adults with active lupus (including kidney inflammation) that hasn't responded to standard treatments. The main goals are to check safety and find the best dose. Researchers will also look for signs that the drug helps cont…

This early-stage study tests a new medicine called MK-1045 in 21 people with lupus or rheumatoid arthritis. The main goal is to check if the drug is safe and tolerable at different doses. Participants must have had their condition for at least 6 months and be on standard treatmen…

This early-stage study tests a single injection of stem cells from donated umbilical cords for people with active lupus. Ten adults will receive the cells alongside their usual care. Researchers will check if the treatment is safe and if it helps reduce disease activity and prote…

This early-stage study tests a new treatment called CC-97540, which uses a patient's own immune cells engineered to target and destroy faulty immune cells causing disease. It is for people with severe forms of lupus, myositis, scleroderma, or rheumatoid arthritis that have not re…

This study tests an experimental oral drug, BI 3000202, in 405 adults with moderate to severe systemic lupus erythematosus (SLE). Participants are randomly assigned to one of four doses of the drug or a placebo, taken daily for a year alongside their usual lupus treatments. The g…

This early-stage study tests a new medicine called LY4298445 in healthy volunteers and people with lupus or rheumatoid arthritis. The main goal is to check if the drug is safe and how the body processes it. About 63 participants will receive either the drug or a placebo, and the …

This study is creating a tool to help doctors diagnose and choose treatments for autoimmune diseases. Researchers will analyze blood samples from 500 children with and without these conditions to find unique molecular patterns. The goal is to make diagnosis faster and treatments …

This study is a registry that will follow 1,000 pregnant women or those planning pregnancy who have autoimmune diseases like lupus or rheumatoid arthritis. Researchers at Duke University want to learn what factors lead to better health for both mother and baby. The goal is to ide…

This study is for mothers with lupus who are already taking the medication anifrolumab and are breastfeeding or pumping. Researchers will measure how much of the drug passes into breast milk and into the baby's blood. The goal is to better understand the safety of anifrolumab dur…

This study compares immune cells from 50 lupus patients with active disease to those with inactive disease. Researchers measure specific receptors on natural killer T cells and monocytes to understand how lupus flares. No new treatment is tested; the goal is to learn more about t…

This study observes about 3,200 adults with moderate-to-severe lupus to see if those taking anifrolumab have more serious infections or cancers than those on standard treatment. Researchers will track hospitalizations, infections needing IV antibiotics, and new cancer diagnoses. …

This study is creating a registry of 1,000 people with lupus (systemic lupus erythematosus or cutaneous lupus) seen at Duke University. Researchers will collect medical information and blood samples over time to learn how lupus changes and how to improve care. Participants must b…

This study looks at whether the immune system ages faster in people with lupus. Researchers will measure specific immune cells and telomeres in 75 adults aged 18–60 with lupus. The goal is to understand the aging process, not to test a new treatment.

This study follows 442 pregnant women with moderate-to-severe lupus to see if the drug anifrolumab affects pregnancy outcomes. Researchers will compare those who took the drug during pregnancy to those who did not. The goal is to gather safety data, not to test a new treatment.

This study tracks 240 pregnant women with lupus who have taken the medication anifrolumab. Researchers want to see if the drug increases the risk of birth defects or other pregnancy problems. The goal is to gather safety information, not to test a new treatment.

This study aims to learn more about how lupus develops and changes over time by observing patients and their relatives. Researchers will collect medical history, blood and urine samples, and genetic material from up to 2,000 participants aged 3 and older. The goal is to better un…

This study is a long-term registry for people with lupus (SLE) who are under a rheumatologist's care. Researchers will collect information during regular doctor visits to learn more about how the disease behaves and how well current treatments work in the real world. No experimen…

This study follows 700 pregnant women with lupus or antiphospholipid syndrome to see if certain proteins in the blood can predict serious pregnancy complications like miscarriage, early delivery, or low birth weight. Researchers will measure immune system proteins and other facto…

This study is building a large database and sample bank from 5,000 adults with rheumatic diseases like rheumatoid arthritis, lupus, and ankylosing spondylitis. Researchers will collect medical information and blood or tissue samples over time to find links between patient outcome…